ARROWHEAD PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$91.94 million for the 12-month period ending 2015-09-30, per its 10-K filed 2015-12-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2015-12-14
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2014-09-30 was -$22.43M.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2014-06-30 was -$11.63M.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2014-03-31 was -$13.98M.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2013-12-31 was -$10.69M.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2015 was -$91.94M.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2014 was -$58.73M.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2013 was -$31.70M.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2012 was -$22.11M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 98 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 101 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 104 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 107 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 110 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 113 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 116 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 119 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 122 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 125 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 128 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 131 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015-09-30 | -$91.94M 10-K · filed 2015-12-14 | |||||||||||||||
| 2014-09-30 | -$22.43M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14 | -$34.06M derived: sum of 2 quarters · filed 2015-12-14 | -$48.04M derived: sum of 3 quarters · filed 2015-12-14 | -$58.73M 10-K · filed 2015-12-14 | ||||||||||||
| 2014-06-30 | -$11.63M 10-Q · filed 2014-08-12 | -$25.61M derived: sum of 2 quarters · filed 2014-08-12 | -$36.29M 10-Q · filed 2014-08-12 | -$50.10M derived: sum of 4 quarters · filed 2015-12-14 | ||||||||||||
| 2014-03-31 | -$13.98M 10-Q · filed 2014-05-06 | -$24.67M 10-Q · filed 2014-05-06 | -$38.47M derived: sum of 3 quarters · filed 2015-12-14 | -$44.65M derived: sum of 4 quarters · filed 2015-12-14 | -$167.19M 10-Q · filed 2014-05-06 | |||||||||||
| 2013-12-31 | -$10.69M 10-Q · filed 2014-02-04 | -$24.49M derived: sum of 2 quarters · filed 2015-12-14 | -$30.67M derived: sum of 3 quarters · filed 2015-12-14 | -$37.61M derived: sum of 4 quarters · filed 2015-12-14 | -$153.20M 10-Q · filed 2014-02-04 | |||||||||||
| 2013-09-30 | -$13.81M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14 | -$19.98M derived: sum of 2 quarters · filed 2015-12-14 | -$26.92M derived: sum of 3 quarters · filed 2015-12-14 | -$31.70M 10-K · filed 2015-12-14 | -$142.52M 10-K · filed 2013-12-18 | |||||||||||
| 2013-06-30 | -$6.18M 10-Q · filed 2014-08-12 | -$13.12M derived: sum of 2 quarters · filed 2014-08-12 | -$17.90M 10-Q · filed 2014-08-12 | -$23.50M derived: sum of 4 quarters · filed 2014-11-25 | -$128.71M 10-Q · filed 2013-08-07 | |||||||||||
| 2013-03-31 | -$6.94M 10-Q · filed 2014-05-06 | -$11.72M 10-Q · filed 2014-05-06 | -$17.32M derived: sum of 3 quarters · filed 2014-11-25 | -$25.56M derived: sum of 4 quarters · filed 2014-11-25 | -$122.54M 10-Q · filed 2013-05-09 | |||||||||||
| 2012-12-31 | -$4.78M 10-Q · filed 2014-02-04 | -$10.38M derived: sum of 2 quarters · filed 2014-11-25 | -$18.62M derived: sum of 3 quarters · filed 2014-11-25 | -$24.20M derived: sum of 4 quarters · filed 2014-11-25 | -$115.60M 10-Q · filed 2013-02-13 | |||||||||||
| 2012-09-30 | -$5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-25 | -$13.84M derived: sum of 2 quarters · filed 2014-11-25 | -$19.42M derived: sum of 3 quarters · filed 2014-11-25 | -$22.11M 10-K · filed 2014-11-25 | -$110.81M 10-K · filed 2012-12-28 | |||||||||||
| 2012-06-30 | -$8.24M 10-Q · filed 2013-08-07 | -$13.82M derived: sum of 2 quarters · filed 2013-08-07 | -$16.51M 10-Q · filed 2013-08-07 | -$19.46M derived: sum of 4 quarters · filed 2013-08-07 | -$105.21M 10-Q · filed 2012-08-13 | |||||||||||
| 2012-03-31 | -$5.58M 10-Q · filed 2013-05-09 | -$8.27M 10-Q · filed 2013-05-09 | -$11.22M derived: sum of 3 quarters · filed 2013-05-09 | -$13.16M derived: sum of 4 quarters · filed 2013-05-09 | -$96.97M 10-Q · filed 2012-05-08 | |||||||||||
| 2011-12-31 | -$2.69M 10-Q · filed 2013-02-13 | -$5.63M derived: sum of 2 quarters · filed 2013-02-13 | -$7.58M derived: sum of 3 quarters · filed 2013-02-13 | -$8.67M derived: sum of 4 quarters · filed 2013-02-13 | -$91.39M 10-Q · filed 2012-02-09 | |||||||||||
| 2011-09-30 | -$2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-28 | -$4.89M derived: sum of 2 quarters · filed 2012-12-28 | -$5.98M derived: sum of 3 quarters · filed 2012-12-28 | -$8.79M 10-K · filed 2012-12-28 | -$88.70M 10-K · filed 2011-12-20 | |||||||||||
| 2011-06-30 | -$1.94M 10-Q · filed 2012-08-13 | -$3.03M derived: sum of 2 quarters · filed 2012-08-13 | -$5.84M 10-Q · filed 2012-08-13 | -$7.46M derived: sum of 4 quarters · filed 2012-08-13 | -$85.76M 10-Q · filed 2011-08-08 | |||||||||||
| 2011-03-31 | -$1.09M 10-Q · filed 2012-05-08 | -$3.89M 10-Q · filed 2012-05-08 | -$5.52M derived: sum of 3 quarters · filed 2012-05-08 | -$5.43M derived: sum of 4 quarters · filed 2012-05-08 | ||||||||||||
| 2010-12-31 | -$2.81M 10-Q · filed 2012-02-09 | -$4.43M derived: sum of 2 quarters · filed 2012-02-09 | -$4.34M derived: sum of 3 quarters · filed 2012-02-09 | |||||||||||||
| 2010-09-30 | -$1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2011-12-20 | -$1.54M derived: sum of 2 quarters · filed 2011-12-20 | -$4.31M 10-K · filed 2011-12-20 | |||||||||||||
| 2010-06-30 | $84.36K 10-Q · filed 2011-08-08 | -$2.69M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |